Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Frequent and Durable Anti-HIV Envelope VIV2 IgG Responses Induced by HIV-1 DNA Priming and HIV-MVA Boosting in Healthy Tanzanian Volunteers.
Joachim A, Msafiri F, Onkar S, Munseri P, Aboud S, Lyamuya EF, Bakari M, Billings E, Robb ML, Wahren B, Mhalu FS, Sandström E, Rao M, Nilsson C, Biberfeld G. Joachim A, et al. Among authors: munseri p. Vaccines (Basel). 2020 Nov 13;8(4):681. doi: 10.3390/vaccines8040681. Vaccines (Basel). 2020. PMID: 33202967 Free PMC article.
Experiences on recruitment and retention of volunteers in the first HIV vaccine trial in Dar es Salam, Tanzania - the phase I/II HIVIS 03 trial.
Bakari M, Munseri P, Francis J, Aris E, Moshiro C, Siyame D, Janabi M, Ngatoluwa M, Aboud S, Lyamuya E, Sandström E, Mhalu F. Bakari M, et al. Among authors: munseri p. BMC Public Health. 2013 Dec 9;13:1149. doi: 10.1186/1471-2458-13-1149. BMC Public Health. 2013. PMID: 24321091 Free PMC article. Clinical Trial.
Performance of a redesigned HIV Selectest enzyme-linked immunosorbent assay optimized to minimize vaccine-induced seropositivity in HIV vaccine trial participants.
Penezina O, Krueger NX, Rodriguez-Chavez IR, Busch MP, Hural J, Kim JH, O'Connell RJ, Hunter E, Aboud S, Higgins K, Kovalenko V, Clapham D, Crane D, Levin AE; HIV Selectest Study Group. Penezina O, et al. Clin Vaccine Immunol. 2014 Mar;21(3):391-8. doi: 10.1128/CVI.00748-13. Epub 2014 Jan 8. Clin Vaccine Immunol. 2014. PMID: 24403525 Free PMC article.
Experiences of social harm and changes in sexual practices among volunteers who had completed a phase I/II HIV vaccine trial employing HIV-1 DNA priming and HIV-1 MVA boosting in Dar es Salaam, Tanzania.
Tarimo EA, Munseri P, Aboud S, Bakari M, Mhalu F, Sandstrom E. Tarimo EA, et al. Among authors: munseri p. PLoS One. 2014 Mar 6;9(3):e90938. doi: 10.1371/journal.pone.0090938. eCollection 2014. PLoS One. 2014. PMID: 24603848 Free PMC article. Clinical Trial.
Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial.
Munseri PJ, Kroidl A, Nilsson C, Joachim A, Geldmacher C, Mann P, Moshiro C, Aboud S, Lyamuya E, Maboko L, Missanga M, Kaluwa B, Mfinanga S, Podola L, Bauer A, Godoy-Ramirez K, Marovich M, Moss B, Hoelscher M, Gotch F, Stöhr W, Stout R, McCormack S, Wahren B, Mhalu F, Robb ML, Biberfeld G, Sandström E, Bakari M. Munseri PJ, et al. PLoS One. 2015 Apr 15;10(4):e0119629. doi: 10.1371/journal.pone.0119629. eCollection 2015. PLoS One. 2015. PMID: 25875843 Free PMC article. Clinical Trial.
43 results